Republican lawmakers are pushing the FDA under the Trump administration to enforce diversity requirements in clinical trials, according to a report from STAT News. Supporters argue the measure is about ensuring drugs and medical devices work across different populations, not about diversity, equity, and inclusion initiatives.
The push comes amid broader political debates over federal diversity programs. Lawmakers emphasized that inclusive trials can improve patient outcomes and reduce safety risks for underrepresented groups. The effort signals a potential bipartisan area of agreement in healthcare regulation.
STAT News reports that the lawmakers are urging the FDA to maintain or strengthen existing guidelines requiring diverse participant enrollment. No specific legislative proposal or executive action has been detailed yet. The agency's response to the request remains unclear.
If enacted, the policy could affect pharmaceutical companies and research institutions conducting clinical trials in the U.S. It may also influence how new drugs are tested for safety and efficacy across racial, ethnic, and demographic groups. Observers note that trial diversity has been a longstanding concern in medical research.
Critics question whether the FDA has the resources or authority to enforce such mandates effectively. Some worry that new requirements could slow drug development without clear benefits.